TY  - JOUR

T1  - nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

JO  - Annals of Oncology

PY  - 2018/06/06

AU  - Yardley DA

AU  - Coleman R

AU  - Conte P

AU  - Cortes J

AU  - Brufsky A

AU  - Shtivelband M

AU  - Young R

AU  - Bengala C

AU  - Ali H

AU  - Eakel J

AU  - Schneeweiss A et al

ED  - 

DO  - DOI: 10.1093/annonc/mdy201

PB  - Elsevier BV

VL  - 29

IS  - 8

SP  - 1763

EP  - 1770

Y2  - 2025/10/10

ER  -